Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $5.99.

  • Ligand Pharmaceuticals' EPS (Basic) rose 163589.74% to $5.99 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.31, marking a year-over-year decrease of 1216.73%. This contributed to the annual value of -$0.22 for FY2024, which is 10708.84% down from last year.
  • Ligand Pharmaceuticals' EPS (Basic) amounted to $5.99 in Q3 2025, which was up 163589.74% from $0.25 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' EPS (Basic) ranged from a high of $5.99 in Q3 2025 and a low of -$2.88 during Q2 2024
  • In the last 5 years, Ligand Pharmaceuticals' EPS (Basic) had a median value of $0.25 in 2025 and averaged $0.63.
  • In the last 5 years, Ligand Pharmaceuticals' EPS (Basic) crashed by 231538.46% in 2024 and then soared by 163589.74% in 2025.
  • Ligand Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.13 in 2021, then tumbled by 30.88% to -$0.17 in 2022, then skyrocketed by 694.47% to $1.04 in 2023, then crashed by 263.44% to -$1.7 in 2024, then soared by 452.41% to $5.99 in 2025.
  • Its EPS (Basic) was $5.99 in Q3 2025, compared to $0.25 in Q2 2025 and -$2.21 in Q1 2025.